Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Debt (2016 - 2025)

Fortress Biotech has reported Non-Current Debt over the past 13 years, most recently at $52.4 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $52.4 million for Q4 2025, down 9.57% from a year ago — trailing twelve months through Dec 2025 was $52.4 million (down 9.57% YoY), and the annual figure for FY2025 was $52.4 million, down 9.57%.
  • Non-Current Debt for Q4 2025 was $52.4 million at Fortress Biotech, up from $47.8 million in the prior quarter.
  • Over the last five years, Non-Current Debt for FBIO hit a ceiling of $91.7 million in Q4 2022 and a floor of $42.6 million in Q3 2021.
  • Median Non-Current Debt over the past 5 years was $54.4 million (2024), compared with a mean of $61.5 million.
  • Biggest five-year swings in Non-Current Debt: soared 114.16% in 2022 and later plummeted 49.77% in 2023.
  • Fortress Biotech's Non-Current Debt stood at $42.9 million in 2021, then surged by 113.64% to $91.7 million in 2022, then crashed by 33.66% to $60.9 million in 2023, then decreased by 4.76% to $58.0 million in 2024, then dropped by 9.57% to $52.4 million in 2025.
  • The last three reported values for Non-Current Debt were $52.4 million (Q4 2025), $47.8 million (Q3 2025), and $50.0 million (Q2 2025) per Business Quant data.